SPINK7/ECRG2 antibody (C-Term)

Catalog No. ABIN1450063

Product Details anti-SPINK7/ECRG2 Antibody

Target: SPINK7/ECRG2 (SPINK7) (Serine Peptidase Inhibitor, Kazal Type 7 (SPINK7))

Binding Specificity: C-Term

Reactivity: Human, Mouse, Rat

Host: Chicken

Clonality: Polyclonal

Conjugate: This SPINK7/ECRG2 antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Enzyme Immunoassay (EIA)

Cross-Reactivity (Details): Species reactivity (tested):Human, Mouse, Rat.

Purification: Affinity chromatography purified via peptide column

Immunogen: 16 amino acid synthetic peptide near the carboxy terminus of Human ECRG2

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Concentration: 1.0 mg/mL

Buffer: PBS containing 0.02 % Sodium Azide as preservative

Preservative: Sodium azide

Precaution of Use: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Avoid repeated freezing and thawing.

Storage: 4 °C/-20 °C

Storage Comment: Store undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.

Target Details for SPINK7/ECRG2

Target: SPINK7/ECRG2 (SPINK7) (Serine Peptidase Inhibitor, Kazal Type 7 (SPINK7))

Alternative Name: ECRG-2 (SPINK7 Products)

Synonyms: Ecg2 antibody, Ecrg2 antibody, OM antibody, ECG2 antibody, ECRG2 antibody, EG408198 antibody, serine peptidase inhibitor, Kazal type 7 antibody, serine peptidase inhibitor, Kazal type 7 (putative) antibody, Spink7 antibody, SPIK7 antibody, SPINK7 antibody

Background: The esophageal cancer-susceptibility gene 2 (ECRG2), also known as SPINK7, is a novel tumor suppressor gene identified from the human esophagus. It interacts directly with metallothionein 2A and urokinase-type plasminogen activator (uPA), and downregulates the activity of uPA, leading to reduced cancer cell migration, invasion and metastasis. ECRG2 forms a complex with uPA and its receptor uPAR, modifying the dynamic association of uPAR with beta1 integrins and disrupting the Src/MAP kinase pathway that normally stimulates cell migration and invasion. ECRG2 may thus represent a novel therapeutic target for cancer.Synonyms: ECG2, Esophagus cancer-related gene 2 protein, MGC133105, MGC133106, SPINK7, Serine protease inhibitor Kazal-type 7, UNQ745/PRO1474

Gene ID: 84651